Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02360059 · ClinicalTrials.gov registry record · Phase 2
Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02360059: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02360059 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02360059, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if metformin can help to control nerve damage (loss of motor or sensory function) that may be caused by treatment with paclitaxel in patients with breast cancer. In this study, metformin will be compared to a placebo. A placebo is not a drug. It looks like the study drug, but it is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.
Interventions
- OTHER Placebo
- DRUG Metformin
- BEHAVIORAL Questionnaires
- OTHER Sensory and Fine-Motor Tests
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02360059
The ClinicalTrials.gov registry entry for NCT02360059 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02360059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02360059 about?
NCT02360059 is a clinical study titled "Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer". The goal of this clinical research study is to learn if metformin can help to control nerve damage (loss of motor or sensory function) that may be caused by treatment with paclitaxel in patients with breast cancer. In this study, metformin will be compared to a placebo. A placebo is not a drug. It ...
What is the current status of trial NCT02360059?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-10. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02360059?
The interventions under investigation include: Placebo (OTHER), Metformin (DRUG), Questionnaires (BEHAVIORAL), Sensory and Fine-Motor Tests (OTHER).
Who is sponsoring clinical trial NCT02360059?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.